2020
PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY
Shore* N, Crawford E, Szmulewitz R, Petrylak D, Holzbeierlein J, Villers A, Azad A, Alcaraz A, Alekseev B, Iguchi T, Gomez-Veiga F, Rosbrook B, Baron B, Haas G, Stenzl A, Armstrong A. PD10-10 IMPACT OF BASELINE DISEASE VOLUME AND PRIOR DOCETAXEL THERAPY ON PROSTATE-SPECIFIC ANTIGEN-RELATED OUTCOMES IN PATIENTS WITH METASTATIC HORMONE-SENSITIVE PROSTATE CANCER TREATED WITH ENZALUTAMIDE PLUS ANDROGEN DEPRIVATION THERAPY. Journal Of Urology 2020, 203 DOI: 10.1097/ju.0000000000000844.010.Peer-Reviewed Original Research
2010
Docetaxel
Phillips C, Petrylak D. Docetaxel. 2010, 133-146. DOI: 10.1007/978-1-60327-829-4_12.Peer-Reviewed Original ResearchCastration-resistant prostate cancerAndrogen deprivation therapyProstate-specific antigenProstate cancerInitial androgen deprivation therapyFirst treatment regimenSecondary hormonal manipulationsStandard chemotherapy combinationTaxane combination therapyFirst-line treatmentUse of docetaxelProstate cancer screeningDeprivation therapyRecurrent diseaseChemotherapy combinationsDocetaxel therapyPSA responseTreatment regimenTreatment optionsCancer screeningDisease progressionHormonal manipulationBetter survivalInvestigational usesSurgical castration